Role of HDL cholesterol in anthracycline-induced subclinical cardiotoxicity: a prospective observational study in patients with diffuse large B-cell lymphoma treated with R-CHOP

Ou,W.,Jiang,T.,Zhang,N.,Lu,K.,Weng,Y.,Zhou,X.,Wang,D.,Dong,Q.,Tang,X.

DOI: https://doi.org/10.1136/bmjopen-2023-074541

IF: 3.006

2024-02-11

BMJ Open

Abstract:Objectives Anthracycline-induced cardiotoxicity is a debilitating cardiac dysfunction for which there are no effective treatments, making early prevention of anthracycline-induced subclinical cardiotoxicity (AISC) crucial. High-density lipoprotein cholesterol (HDL-C) plays a role in cardioprotection, but its impact on AISC remains unclear. Our study aims to elucidate the protective capacity of HDL-C in AISC in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone and rituximab). Design Prospective observational study. Setting Conducted in China from September 2020 to September 2022. Participants Primary outcome measures Serum biomarkers, 2D speckle tracking echocardiography and conventional echocardiography were measured at baseline, at the end of the third and sixth cycles of R-CHOP and 6 and 12 months after chemotherapy. Results 24 patients experienced AISC, while 10 did not. 36 patients were lost to follow-up and death. Cox regression analysis showed that higher levels of HDL-C were associated with a significantly lower risk of AISC (unadjusted HR=0.24, 95% CI 0.09 to 0.67, p=0.006; adjusted HR=0.27, 95% CI 0.09 to 0.79, p=0.017). Patients without AISC had a more stable and higher HDL-C level during the follow-up period. HDL-C levels significantly decreased from the end of the third cycle of chemotherapy to the end of the sixth cycle of chemotherapy in all patients (p=0.034), and particularly in the AISC group (p=0.003). The highest level of HDL-C was significantly higher in patients without AISC than in those with AISC (1.52±0.49 vs 1.22±0.29, p=0.034). Conclusions Our study suggests that higher HDL-C levels may associate with lower AISC risk in patients with DLBCL treated with R-CHOP. HDL-C could be a cardioprotective target, but further research is needed to confirm its benefits and limitations. Study registration number Study registration number: ChiCTR2100054721

medicine, general & internal

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the protective role of high - density lipoprotein cholesterol (HDL - C) in anthracycline - induced subclinical cardiotoxicity (AISC). Specifically, the study aims to clarify whether HDL - C can reduce the risk of AISC in patients with diffuse large B - cell lymphoma (DLBCL) who are treated with the R - CHOP chemotherapy regimen.

### Research Background

Anthracyclines (such as doxorubicin) are commonly used anticancer drugs. Although their efficacy is significant, long - term use may lead to severe cardiotoxicity, manifested as myocardial dysfunction and eventually heart failure. This cardiotoxicity is usually irreversible, and there is currently no effective treatment method. Therefore, early prevention and detection of anthracycline - induced cardiotoxicity are crucial.

### Research Objectives

1. **Evaluate the relationship between HDL - C and AISC**: Through a prospective observational study, explore whether HDL - C levels are related to the incidence of AISC.
2. **Preliminarily explore the changes of HDL - C in AISC patients**: Analyze the fluctuations of HDL - C levels in patients with and without AISC, and the impact of these fluctuations on cardiac function.

### Main Findings

- **Higher HDL - C levels are associated with a lower risk of AISC**: Cox regression analysis shows that higher HDL - C levels are associated with a significantly lower risk of AISC (unadjusted HR = 0.24, 95% CI 0.09 to 0.67, p = 0.006; adjusted HR = 0.27, 95% CI 0.09 to 0.79, p = 0.017).
- **Changes in HDL - C levels**: During the entire chemotherapy process, the HDL - C levels of all patients decreased significantly from the end of the third cycle to the end of the sixth cycle (p = 0.034), especially more obvious in the AISC group (p = 0.003).
- **HDL - C levels in patients without AISC are more stable and higher**: The HDL - C levels in patients without AISC remained high and stable throughout the follow - up period, while the HDL - C levels in AISC patients decreased significantly.

### Conclusion

This study shows that higher HDL - C levels may be associated with a lower risk of AISC, suggesting that HDL - C may play a protective role in anthracycline - induced cardiotoxicity. However, further research is needed to confirm the benefits and limitations of HDL - C as a cardioprotective strategy.

### Formula Presentation

To ensure the correctness and readability of the formulas, the following are some of the formulas involved in the paper:

- Hazard ratio (HR) and its confidence interval (CI):
\[
\text{HR} = 0.24, \quad 95\% \text{ CI} = [0.09, 0.67], \quad p = 0.006
\]
\[
\text{Adjusted HR} = 0.27, \quad 95\% \text{ CI} = [0.09, 0.79], \quad p = 0.017
\]

- Definition of HDL - C levels:
\[
\text{High HDL - C} \geq 1.16 \, \text{mmol/L}
\]
\[
\text{Low HDL - C} < 1.16 \, \text{mmol/L}
\]

It is hoped that this information can help you better understand the research content and conclusions of this paper. If you have more questions or need further information, please feel free to let us know.